EVQLV Wins Columbia Venture Competition

Apr 29, 2020 | News | 0 comments

Daniel Gigante

EVQLV is excited to announce we took first place in Columbia Engineering’s Venture Competition (CVC). We’ve included a snippet from the announcement below. If you’d like to read the official release, you can do so here.

In the Technology Challenge, avoMD and EVQLV each took first place and $20,000 in funding. avoMD, led by cofounders Joongheum Park, Yair Saperstein, and Laurence Coman, is a digital point-of-care personal assistant made for doctors by doctors. EVQLV is an artificial intelligence company focused on accelerating biologic therapies. The company was founded by Andrew Satz and Bret Averso, who aimed to leverage AI to computationally design innovative antibody candidates that can be quickly synthesized and validated. Dialetica, developing wearables for managing advanced-stage kidney failure, placed in third, winning $10,000 in funding.

We would like to give a special thanks to all fellow companies, the wonderful judges, and of course, Columbia Engineering.


Submit a Comment

Your email address will not be published. Required fields are marked *

Large Pharma’s Embrace of Artificial Intelligence

The benefits of computational drug development are well known and accepted by many in the pharmaceutical space. However, since the onset of the global pandemic, consensus went from it being an interesting concept that was almost certainly the future, to something we need implemented as soon as possible. This is one of the few silver linings of the coronavirus outbreak.

The depth, vision and progress of EVQLV

Our CEO, Andrew Satz, recently spoke at Columbia University School of General Studies’ “Alumni in Action.” The subject of his talk was artificial intelligence. One of the questions posed to Andrew was what we were doing outside of coronavirus, along with the long term plans of our company

EVQLV Applies Proprietary AI Technology in Collaboration with Twist Bioscience to Discover and Validate Novel Antibody Therapies

EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a collaboration with Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, to discover novel antibody-based therapies.

EVQLV’s Evolutionary Algorithm Explained

Brett Averso (CTO, EVQLV) and Bhoomika Kumar (SciTech intern, EVQLV) teamed up to provide a high-level overview¬†of how EVQLV’s evolutionary algorithm works.

Andrew Satz on the Talent Finders Podcast

EVQLV’s CEO, Andrew Satz, joined Kerrin Black of the Talent Finders Podcast to discuss his entrepreneurial journey, some of the challenges facing AI for drug discovery, his legacy and much more.

Pin It on Pinterest